March 10, 2014 | Israeli company XTL Biopharmaceuticals, which is focused on developing a treatment for lupus, has filed with the US Securities and Exchange Commission (SEC) to hold a public offering on Nasdaq in an attempt to raise $40 million. The proceeds will be directed towards various clinical trials the company is planning.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments